Skip to content

Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis

Contribution of Whole Body Muscle MRI for Early Diagnosis of Amyotrophic Lateral Sclerosis.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04868994
Acronym
MIDALS
Enrollment
50
Registered
2021-05-03
Start date
2021-06-01
Completion date
2024-12-31
Last updated
2024-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis With Dementia

Keywords

Amyotrophic, Sclerosis

Brief summary

Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers, this diagnosis is based, among other things, on the demonstration of the diffusion of signs of denervation by electroneuromyography (ENMG). The objective of this study is to improve the earliness and the level of diagnostic certainty by better demonstrating the diffusion of the denervation process by whole body muscular MRI.

Detailed description

The objective of this study is to show that the combination of ENMG and whole body muscle MRI (WB-MRI) can increase the diagnosis of definite ALS at the onset of the disease For 50 consecutive patients with suspected ALS, the present study will prospectively perform needle electromyography (EMG) and muscle analyses on whole body MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria. On whole body MRI acquisition, for 83 muscles, will be explored fatty infiltration and atrophy on fat images (chronic denervation) and muscle edema on water images (acute denervation). EMG studies will be performed in at least 10 muscles (tongue, biceps brachii, first dorsalis interosseous, T10 paraspinalis, vastus lateralis, and tibialis anterior). Diagnostic classification according EMG and/ or MRI abnormalities in bulbar and the 3 spinal regions will be compared independently.

Interventions

DIAGNOSTIC_TESTWhole Body MRI and ENMG

Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Consent form signed by the patient * Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined) * Clinical assessment of upper motor neuron involvement * Electrophysiologic assessment of lower motor neuron involvement

Exclusion criteria

* inability to give informed consent * a contraindication to MRI * respiratory failure impairing ability to lie flat in the scanner. * Patient placed under judicial protection or under another protective regime, * Females who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic certainty 1.ENMG according to El Escorial revised criteria using ENMG alone, MRI alone and ENMG+MRI to define denervation diffusion1 monthnumber of patients classified as possible, probable or certain according to El Escorial criteria using ENMG alone, IMR alone and ENMR+MRI

Secondary

MeasureTime frameDescription
Define precise topographic and characteristic of muscle involvement in ALS by MRI1 monthnumber of patients with concordance between ENMG and MRI for the detection of denervation

Countries

France

Contacts

Primary ContactPascal CINTAS, MD PHD
cintas.p@chu-toulouse.fr05 61 77 94 40
Backup ContactAnne Cecile Coville
(05345) 58700

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026